Farallon Capital Management LLC Boosts Stake in Boston Scientific Corporation $BSX

Farallon Capital Management LLC boosted its position in Boston Scientific Corporation (NYSE:BSX) by 19.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,746,557 shares of the medical equipment provider’s stock after purchasing an additional 765,500 shares during the period. Boston Scientific makes up approximately 1.9% of Farallon Capital Management LLC’s investment portfolio, making the stock its 13th biggest holding. Farallon Capital Management LLC owned approximately 0.32% of Boston Scientific worth $463,406,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the business. Brighton Jones LLC boosted its holdings in Boston Scientific by 0.8% during the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after acquiring an additional 226 shares during the period. Campbell & CO Investment Adviser LLC purchased a new stake in Boston Scientific in the second quarter worth $249,000. Advisors Capital Management LLC lifted its position in shares of Boston Scientific by 46.5% during the second quarter. Advisors Capital Management LLC now owns 6,446 shares of the medical equipment provider’s stock worth $692,000 after purchasing an additional 2,046 shares during the last quarter. Foundations Investment Advisors LLC lifted its position in shares of Boston Scientific by 16.1% during the second quarter. Foundations Investment Advisors LLC now owns 4,178 shares of the medical equipment provider’s stock worth $449,000 after purchasing an additional 579 shares during the last quarter. Finally, Empower Advisory Group LLC boosted its stake in shares of Boston Scientific by 188.9% during the second quarter. Empower Advisory Group LLC now owns 94,747 shares of the medical equipment provider’s stock valued at $10,177,000 after purchasing an additional 61,954 shares during the period. Institutional investors own 89.07% of the company’s stock.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Neutral Sentiment: Zacks published a recap explaining why Boston Scientific dipped more than the broader market, noting recent volatility around the company. Useful for context on short‑term market reaction. Article Title
• Negative Sentiment: Citigroup lowered its price target for Boston Scientific to $94.00 — a formal analyst downgrade that can weigh on sentiment and may lead some funds to reprice positions. Article Title
• Negative Sentiment: Levi & Korsinsky (reported via PR Newswire) and others say a filed class action alleges Boston Scientific executives misrepresented U.S. electrophysiology procedure volumes — this is the substantive allegation that could lead to discovery, potential damages or settlement risk. Investors should watch pleadings and any company response. Article Title
• Negative Sentiment: Multiple plaintiff law firms (Rosen, Pomerantz, Glancy Prongay Wolke, Robbins Geller, Faruqi, Gross, Bernstein Liebhard, etc.) have issued shareholder alerts and deadline reminders (lead‑plaintiff motions due May 4, 2026). The coordinated outreach increases the likelihood of consolidated litigation and underscores ongoing legal scrutiny. Article Title

Boston Scientific Stock Performance

BSX stock opened at $69.15 on Monday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08. The business has a 50-day moving average price of $82.47 and a 200 day moving average price of $93.21. The company has a market capitalization of $102.61 billion, a P/E ratio of 35.64, a PEG ratio of 0.97 and a beta of 0.69. Boston Scientific Corporation has a 1-year low of $67.56 and a 1-year high of $109.50.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. The company had revenue of $5.29 billion during the quarter, compared to analyst estimates of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The firm’s revenue for the quarter was up 15.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, equities research analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on BSX. Wells Fargo & Company reduced their price target on shares of Boston Scientific from $125.00 to $94.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. Morgan Stanley lowered their price objective on shares of Boston Scientific from $130.00 to $118.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. BTIG Research restated a “buy” rating on shares of Boston Scientific in a research note on Wednesday, February 4th. Mizuho reduced their target price on shares of Boston Scientific from $140.00 to $115.00 and set an “outperform” rating on the stock in a research report on Thursday, February 5th. Finally, Royal Bank Of Canada decreased their price target on shares of Boston Scientific from $130.00 to $115.00 and set an “outperform” rating for the company in a research note on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $108.00.

Insider Buying and Selling at Boston Scientific

In other news, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the sale, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.50% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.